机构:[1]Zhengzhou Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, 1 East Jian She Rd, Zhengzhou 450052, Henan, Peoples R China[2]Henan Engn Technol Res Ctr Organ Transplantat, Zhengzhou, Peoples R China[3]Henan Res & Dev Int Joint Lab Organ Transplantat, Zhengzhou, Peoples R China[4]Wuhan Univ, Tongren Hosp, Wuhan, Peoples R China[5]Wuhan Third Hosp, Wuhan, Peoples R China[6]Zhengzhou Univ, Dept Surg, Affiliated Hosp 1, Zhengzhou, Peoples R China[7]Wuhan Univ, Dept Cardiol, Renmin Hosp, Wuhan, Peoples R China
Background and Aims Hepatic ischemia-reperfusion injury (IRI) is a common complication of hepatectomy and liver transplantation. However, the mechanisms underlying hepatic IRI have not been fully elucidated. Regulator of G-protein signaling 14 (RGS14) is a multifunctional scaffolding protein that integrates the G-protein and mitogen-activated protein kinase (MAPK) signaling pathways. However, the role of RGS14 in hepatic IRI remains unclear. Approach and Results We found that RGS14 expression increased in mice subjected to hepatic ischemia-reperfusion (IR) surgery and during hypoxia reoxygenation in hepatocytes. We constructed global RGS14 knockout (RGS14-KO) and hepatocyte-specific RGS14 transgenic (RGS14-TG) mice to establish 70% hepatic IRI models. Histological hematoxylin and eosin staining, levels of alanine aminotransferase and aspartate aminotransferase, expression of inflammatory factors, and apoptosis were used to assess liver damage and function in these models. We found that RGS14 deficiency significantly aggravated IR-induced liver injury and activated hepatic inflammatory responses and apoptosis in vivo and in vitro. Conversely, RGS14 overexpression exerted the opposite effect of the RGS14-deficient models. Phosphorylation of TGF-beta-activated kinase 1 (TAK1) and its downstream effectors c-Jun N-terminal kinase (JNK) and p38 increased in the liver tissues of RGS14-KO mice but was repressed in those of RGS14-TG mice. Furthermore, inhibition of TAK1 phosphorylation rescued the effect of RGS14 deficiency on JNK and p38 activation, thus blocking the inflammatory responses and apoptosis. Conclusions RGS14 plays a protective role in hepatic IR by inhibiting activation of the TAK1-JNK/p38 signaling pathway. This may be a potential therapeutic strategy for reducing incidences of hepatic IRI in the future.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81971881]; Central-China Science and Technology Innovative Talent Program in Henan Province [214200510027]; Medical Science and Technology Program of Henan Province China [SBGJ2018002, SBGJ2018023, SB201901045, GDXZ2019005]
第一作者机构:[1]Zhengzhou Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, 1 East Jian She Rd, Zhengzhou 450052, Henan, Peoples R China[2]Henan Engn Technol Res Ctr Organ Transplantat, Zhengzhou, Peoples R China[3]Henan Res & Dev Int Joint Lab Organ Transplantat, Zhengzhou, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Zhengzhou Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, 1 East Jian She Rd, Zhengzhou 450052, Henan, Peoples R China[2]Henan Engn Technol Res Ctr Organ Transplantat, Zhengzhou, Peoples R China[3]Henan Res & Dev Int Joint Lab Organ Transplantat, Zhengzhou, Peoples R China[*1]Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1, East Jian She Road, Zhengzhou, Henan Province, 450052, China.
推荐引用方式(GB/T 7714):
Zhang Jia-Kai,Ding Ming-Jie,Liu Hui,et al.Regulator of G-protein signaling 14 protects the liver from ischemia-reperfusion injury by suppressing TGF-beta-activated kinase 1 activation[J].HEPATOLOGY.2022,75(2):338-352.doi:10.1002/hep.32133.
APA:
Zhang, Jia-Kai,Ding, Ming-Jie,Liu, Hui,Shi, Ji-Hua,Wang, Zhi-Hui...&Zhang, Shui-Jun.(2022).Regulator of G-protein signaling 14 protects the liver from ischemia-reperfusion injury by suppressing TGF-beta-activated kinase 1 activation.HEPATOLOGY,75,(2)
MLA:
Zhang, Jia-Kai,et al."Regulator of G-protein signaling 14 protects the liver from ischemia-reperfusion injury by suppressing TGF-beta-activated kinase 1 activation".HEPATOLOGY 75..2(2022):338-352